Resultado de búsqueda
28 de may. de 2024 · VAP is a significant source of increased illness and death. This indicator measures the number of Ventilator associated pneumonias happening in the ICU per 1000 ventilator days. What does it indicate?
29 de may. de 2024 · Ventilator-associated pneumonia (VAP) is a serious and potentially life-threatening complication commonly encountered in critically ill patients receiving mechanical ventilation. It is characterized by inflammation of the lung parenchyma due to an infection that arises 48 hours after endotracheal intubation. VAP poses significant ...
20 de may. de 2024 · Indications. The chest radiograph is performed for a broad content of indications, including but not limited to 1-4: respiratory disease. cardiac disease. hemoptysis. suspected pulmonary embolism. investigation of tuberculosis. pneumonia. pneumothorax. suspected metastasis. follow up of known disease to assess progress. chronic dyspnea. trauma.
13 de may. de 2024 · Results. A total of 184 individuals (average age 61.85 ± 13.25 years, 73.37% male) were enrolled, and the rate of VAP occurrence was found to be 57.07%. Factors such as the Glasgow Coma Scale (GCS) score, duration of stay in the Intensive Care Unit (ICU), dysphagia, Fazekas scale 2 and admission diastolic blood pressure were found to be associated with the occurrence of VAP in the nomogram ...
16 de may. de 2024 · The acetabular angle, also known as Sharp angle 6, is a radiographic measurement most commonly used to evaluate potential developmental dysplasia of the hip (DDH) in children and acetabular dysplasia in adults.
21 de may. de 2024 · Transcatheter aortic valve implantation or replacement ( TAVI/TAVR) is a technique to replace the aortic valve through a transvascular or transapical approach. Compared to traditional open aortic valve replacement with sternotomy and a heart-lung bypass machine, the TAVI technique is less invasive and can be performed on the beating heart.
Hace 6 días · Vascular adhesion protein-1 (VAP-1) drives inflammation in liver disease, and provision of an antibody against VAP-1 blunts fibrosis in murine models of liver injury. METHODS AND ANALYSIS: BUTEO is a single-arm, two-stage, open-label, multi-centre, phase II clinical trial.
